Table 2. Results showing specificity of the 18 mRNA markers used in various body fluids or tissues by endpoint PCR singleplexes and real-time PCR.
| Body fluid | ||||||||||
| Body fluid Markers | Blood | Saliva | Semen | Vaginal secretion | Menstrual blood | Oral mucosa | Urine | Nasal secretion | Sweat | Skin |
| HBB | ++ | − | − | −(80%) | ++ | − | + | −(87.5%) | − | − |
| GLY | + | − | − | − | (+) | − | − | − | − | − |
| PBGD | (+) | − | − | − | − | − | − | − | − | − |
| STATH | − | + | − | − | − | (+)(75%) | − | + | − | − |
| HTN3 | − | ++ | − | − | − | + | − | − | − | − |
| PRM2 | − | − | ++ | − | − | − | − | − | − | − |
| TGM4 | − | − | ++ | − | − | − | +(m) | − | − | − |
| MUC4 | − | − | − | + | + | − | +(f) | − | − | − |
| HBD1 | − | − | − | + | + | (+) | (+)(f) | + | − | (+) |
| MMP7 | − | − | − | −(80%) | + | − | + | − | − | − |
| MMP11 | − | − | − | − | + | − | − | − | − | − |
| KRT4 | − | + | − | + | + | ++ | +(f) | + | − | + |
| UMOD | − | − | − | − | − | − | + | − | − | − |
| DCD | − | − | − | − | − | − | − | − | + | − |
| LOR | − | (+) | − | + | + | + | (+) | + | (+) | + |
| CST6 | (+) | + | (+) | + | (+) | + | (+) | (+) | (+) | + |
| GAPDH | + | (+) | + | + | + | + | (+) | (+) | (+) | + |
For all markers consisting of 4–16 individuals(as described in 2.2.1) were analyzed. Three separate experiments were analyzed. Initial total RNA was 1 ng.
1. ++ means dCt<10, peak heights>4000 RFU; + means 10≤dCt≤20, peak height 500≤RFU≤4000;
(+) means 20<dCt≤23, peak height 100≤RFU<500; - means dCt>23, peak height <100 RFU;
2. m = adult male; f = female;
3. (Percentage) indicated the percentage of individuals showed positive or negative results of the marker in the tested body fluids or tissues;
4. ‘+’ or ‘−’ means 100% positive or negative for that marker.